We studied the metabolism of lipoprotein-proteoglycan complexes by macrophage-derived foam cells. Foam cells were isolated from atherosclerotic rabbit aortas. ApoB-lipoproteinproteoglycan complex was isolated from human aorta fibrous plaque lesions and LDL-proteoglycan complex was formed in vitro. Both in vitro and in vivo complexes stimulated cholesteryl ester synthesis in foam cells by a dose-dependent, saturable process that resulted in the intracellular accumulation of cholesteryl ester. Stimulation ofcholesteryl ester synthesis was linear with time over a 32-h period. Polyinosinic acid inhibited the stimulation of cholesteryl ester synthesis by the complexes by 32-37%, whereas cytochalasin D only produced a 6-16% inhibition. Foam cells degraded '25I-LDL-proteoglycan complex and 125I-acetyl LDL in a saturable, dose-dependent manner. Excess unlabeled acetyl-LDL inhibited the degradation of '251-LDL-proteoglycan complex by 52%, while LDL had no effect. Similarly, excess unlabeled complex suppressed the degradation of '251-acetyl-LDL by 48%. Foam cells degraded 1251. methyl-LDL-proteoglycan complex to the same extent as 1251_ LDL-proteoglycan complex. These results show that foam cells from atherosclerotic lesions metabolize lipoprotein-proteoglycan complexes predominantly via receptor-mediated endocytosis and consequently continue to accumulate intracellular cholesteryl ester. (J. Clin. Invest. 1993. 91:1011-1018 
Introduction
Foam cells of atherosclerotic lesions originate predominantly from macrophages (1) (2) (3) (4) (5) . It is well recognized that the cholesteryl ester that accumulates in foam cells is derived from LDL; however, the in vivo mechanism of LDL-mediated cholesteryl ester accumulation in macrophages is not known. In vitro, macrophages accumulate cholesteryl ester when exposed to acetyl-LDL (6) , malondialdehyde modified LDL (7), oxidized LDL (8) , LDL isolated from atherosclerotic lesions (9) , and aggregated LDL (10), but not native LDL.
Several studies including our own have shown that complexes of LDL and arterial wall proteoglycan also promote cholesteryl ester accumulation in macrophages in vitro (1 1-14) . The demonstration of the existence of lipoprotein-proteoglycan complexes in vivo and their successful isolation from atherosclerotic lesions in humans and animals ( 15, 16) have led to the hypothesis that the uptake of such complexes by macrophages could cause foam cell formation in vivo. Our recent studies have provided support to this hypothesis ( 17) . Apo B-lipoprotein-proteoglycan complexes isolated from fatty streaks and fibrous plaques of human aorta were taken up by human monocyte-derived macrophages and consequently induced cellular cholesteryl ester synthesis and accumulation.
In an attempt to obtain further experimental evidence in support of this hypothesis, we have turned to the foam cells.
Foam cells isolated from atherosclerotic lesions take up chemically modified LDL and apo E-containing lipoproteins (18) (19) (20) . In contrast, very little native LDL is metabolized by these cells (20) . The uptake of lipoprotein-proteoglycan complexes by foam cells followed by stimulation of cholesteryl ester formation would strongly indicate a role for proteoglycans in foam cell formation. Therefore, in this study we have investigated the metabolism of lipoprotein-proteoglycan complexes by freshly isolated foam cells from atherosclerotic lesions of rabbit aorta. The results show that these complexes are taken up by rabbit aorta foam cells by a receptor-mediated mechanism and they stimulate further intracellular accumulation of cholesteryl ester.
Methods

Materials
Opti-MEM I reduced serum media was obtained from GIBCO BRL (Gaithersburg, MD). Collagenase (CLSPA) came Lipoproteins LDL (d = 1.02-1.055 g/ml) was isolated from pooled human serum by sequential ultracentrifugation (21) . 0.05% EDTA, 10 ,uM butylated hydroxytoluene, and 20 mM PMSF were added to the blood immediately after collection. The purity ofLDL was determined by agarose gel electrophoresis. LDL was acetylated by the repeated addition of acetic anhydride (22) , which modified 91% of available free amino groups. Reductive methylation of LDL was performed as described by Weisgraber et al. (23) . This modified 82% of available free amino groups. Aggregated LDL was prepared by vortexing LDL for 30 S (10). Lipoproteins were radiolabeled with carrier free Na 1251 (24) .
Proteoglycan
A chondroitin sulfate-dermatan sulfate proteoglycan aggregate was prepared from bovine aorta. The isolation and characterization of the proteoglycan has been reported previously ( 11) . Briefly, bovine aorta intima-media slices were extracted with 0.5 M guanidine hydrochloride in the presence of protease inhibitors. The extract was subjected to CsCl isopycnic density gradient centrifugation at a loading density of 1.60 g/ml. The bottom two-fifths ofthe gradient represented proteoglycan aggregate. The aggregate contained 18% hyaluronic acid, 19% dermatan sulfate, and 63% chondroitin sulfate.
Lipoprotein-proteoglycan complexes
In vitro complexes. Complexes of LDL or '25I-LDL and the proteoglycan aggregate were prepared essentially as described previously (25) . In brief, 0.1 ml of proteoglycan solution ( 18.2 ,ug uronic acid or 60 yg glycosaminoglycan) was mixed with LDL or '251I-LDL ( 150 Mg cholesterol). CaC12 (final concentration 30 mM) was added to the mixture followed by appropriate volumes of 0.001 M Tris-HCl, pH 7.4, to bring the final volume to 1.5 ml. After 15 min at room temperature, the precipitated LDL-proteoglycan complex wassedimented bycentrifugation (8,000 g for 5 min). The complex was solubilized in the foam cell culture medium (see below) and filtered through a 0.45-,MM filter before use in various experiments. Cholesterol and uronic acid contents of the complex were assayed and used as measures of LDL and proteoglycan, respectively. Almost all of the LDL and 80% of the proteoglycan were recovered in the complex.
In vivo complex. Lipoprotein-proteoglycan complex was isolated from fibrous plaque lesions of human aorta. Details of the isolation and purification procedures have been reported ( 17) . Briefly, human aortas were obtained at autopsy within 12 h of death. Fibrous plaque lesions from four to five aortas were pooled and extracted with 0.15 M NaCl and 0.05 M Tris-HCl, pH 7.4, containing protease inhibitors (0.1 M e-amino-n-caproic acid, 0.005 M benzamidine hydrochloride, 0.005 M N-ethylmaleimide, 0.001 M PMSF), and antioxidants (0.05% EDTA, 20MgM butylated hydroxytoluene):.Fractionation of the extract on a column of Bio-Gel A-50m yielded two complexes containing both lipoprotein and proteoglycan, one eluting at the V. (complex 1) and the other eluting in the inclusive volume ahead of human LDL (complex 2); lipoprotein-proteoglycan complex 2 was further purified by anti-apoB-affinity chromatography and used in this study.
Foam cells
Foam cells were prepared by a modification of the procedures described previously (20, 26) . 46 male New Zealand white rabbits weighing 2-2.3 kg were fed a high cholesterol (2%) diet for 1 wk. The aorta and left iliac artery of each animal were deendothelialized with a Fogarty embolectomy catheter and the rabbits were continued on the high cholesterol diet for an additional 12 wk. Recently, Rosenfeld et al. reported that this procedure improved the yield of foam cells (20) . Rabbits were killed by intravenous injection of sodium pentobarbital and aortas and left iliac arteries were quickly transferred to sterile HBSS containing glucose, amino acids, and antibiotics (26) .
Atherosclerotic lesions, which covered almost the entire vessel surface, were dissected aseptically and chopped into -0.5-mm pieces. The tissue pieces were placed in fresh Hanks' solution with the supplements in which the calcium concentration had been reduced to 0.2 mM (10 ml/g tissue). The lesions were digested with a mixture of collagenase (600 U/ml), elastase (5 U/ml), and soybean trypsin inhibitor (1 mg/ml) at 37°C with shaking for 30 min. The enzyme-tissue mixture was filtered through a 100-Mum mesh nylon screen (Whatman Inc., Clifton, NJ) in a Swinex filter holder (Millipore Corp.; Bedford, MA). The tissue chunks on the filter were returned to the digestion flask. The filtrate was centrifuged at 2,300 rpm for 5 min in a desk top centrifuge (model TJ-6; Beckman Instruments, Inc., Fullerton, CA) and the supernatant was returned to the digestion flask. The cells from the centrifugation were washed with supplemented Hanks' solution containing 10% fetal bovine serum and kept in supplemented Hanks' solution at 370C. The remaining tissue was digested for 30 min and cells were separated and washed as before. This procedure was repeated five times. The cells from all digestions were combined and pelleted by centrifugation. The cell pellet was resuspended in 1-2 ml of 90% Percoll in calcium-and magnesium-free Hanks' solution and layered under a preformed gradient of 40% Percoll in calcium-and magnesium-free Hanks' solution (27). The solution was centrifuged at 400 g for 20 min in a swinging bucket rotor (model TH-4; Beckman Instruments, Inc.). The top fraction (d < 1.06 g/ml) containing exclusively the foam cells was removed and the cells were washed with Opti-MEM I containing 0.5% fetal bovine serum (medium A). The cells were plated in the above medium in 24-well dishes at a density of 5 X 105 cells/well and incubated at 370C in a humidified CO2 (5%) incubator. Nonadherent cells were washed offthe wells after 24 h and the adherent foam cells were used immediately for the experiments. Viability ofthe cells was assessed by their ability to exclude trypan blue. The purity of the foam cells was established by immunohistochemical staining with anti-rabbit macrophage monoclonal antibody RAM-1 1 (28).
Macrophages
Human monocyte-derived macrophages were isolated as described previously ( 17 ) . The monocytes were cultured in RPMI-1640 containing 20% homologus serum (vol/vol), penicillin ( 100 U/ml), and streptomycin (100 jug/ml). The cells were maintained in culture for 8 d with medium changes every 3 d before they were used for experiments.
Cholesterol esterification
The ability of various ligands to stimulate cholesteryl ester synthesis in foam cells was determined essentially as described previously ( 11) . Briefly, foam cells were incubated in medium A containing 0. 
Cholesteryl ester accumulation
For cellular cholesterol mass determination, foam cells were incubated with various ligands for 48 h. [3H]Cholesterol was then added as an internal standard and cellular lipids were extracted with hexane/isopropanol (3:2, vol/vol). Cholesterol and cholesteryl ester were separated by thin layer chromatography and quantitated by the procedure ofBowman and Wolf (29) with the modification that the chromophore was measured spectrofluorometrically.
Degradation of'25I-labeled ligands
Cellular degradation of various 125I-labeled ligands was assayed as described previously ( 11) . Foam cells were incubated in medium A containing '25M-labeled ligands and other additions as required by individual experiments. After 6 h at 37°C, the culture medium was assayed for trichloroacetic acid soluble (noniodide) radioactivity. Results were corrected for small amounts of acid-soluble radioactivity formed in parallel cell-free incubations.
Analytical methods
Uronic acid was assayed by the method of Blumenkrantz and AsboeHansen (30) and protein by a modified Lowry procedure (31 ) . Cholesterol determination was done with a commercial enzymatic reagent kit (Autoflow Cholesterol 236691; Boehringer Mannhein Diagnostics, Houston, TX). Other assays were done as described previously (17) . (25) . Hence, there existed a possibility that the lipoprotein-proteoglycan complexes might dissociate in cholesteryl ester synthesis induced by fibrous plaque complex and in vitro LDL-proteoglycan complex by 32 and 37%, respectively. In contrast, the drug completely inhibited acetyl-LDLmediated cholesteryl ester synthesis. Cytochalasin D (2 ,ug/ml) had no effect on cholesteryl ester formation elicited by acetyl-LDL, and it inhibited cholesteryl ester formation stimulated by fibrous plaque complex and the in vitro complex by only 6 and 16%, respectively. In contrast, the drug inhibited the degradation ofaggregated LDL by 90% (data not shown). These results thus suggest that while the scavenger receptor might be involved in the recognition of the complexes, phagocytosis plays no significant role.
Degradation of2' I-LDL-proteoglycan complex. To understand further the mechanism of recognition of the complexes, we then studied the degradation of '25I-LDL-proteoglycan complex by foam cells (Fig. 6 ). The cells degraded '251I-LDL- proteoglycan complex and '251I-acetyl-LDL in a dose-dependent manner. Degradation of both ligands appeared to reach saturation at 100 ,gg cholesterol/ml. The cells degraded very little 1251I-LDL.
In studies to be published elsewhere (Vijayagopal, P., S. R. Srinivasan, B. Radhakrishnamurthy, and G. S. Berenson, manuscript submitted for publication), we performed binding studies of '251-LDL-proteoglycan complexes to human monocyte-derived macrophages at 4VC. Binding was concentration dependent and saturable. Scatchard analysis of the data gave a Kd of 1.5 x 10-8 M, which was 1.75 times higher than the Kd reported for LDL in macrophages (34) .
Having established that the foam cells degrade a significant amount of 125I-LDL-proteoglycan complex, we then performed competitive degradation experiments using other ligands. The results are presented in Table II . A 50-fold excess of unlabeled acetyl-LDL inhibited the catabolism of '25I-LDLproteoglycan complex by 52%. Excess unlabeled LDL had no effect. In contrast, a 50-fold excess of unlabeled LDL-proteoglycan complex inhibited the degradation of the labeled complex by 92%. In the reverse competition experiment, excess LDL-proteoglycan complex suppressed the degradation of '25I-acetyl LDL by 48%. Neither excess complex nor acetyl-LDL inhibited the degradation of 125I-LDL (data not shown).
These results further emphasized a role for the scavenger receptor in the uptake of lipoprotein-proteoglycan complexes in foam cells. Earlier, we reported that excess proteoglycan and hyaluronic acid did not inhibit the binding and degradation of'25-I-LDL-proteoglycan complex in macrophages (35, 36).
Degradation of 125I-methyl LDL-proteoglycan complex. The lack of competition by LDL against the degradation of '25I-LDL-proteoglycan complex suggested that the uptake of the complex was not through the apo B, E receptor. To further confirm this, we studied the degradation of _25I-methyl-LDLproteoglycan complex by foam cells. While methylation of LDL inhibits uptake via the apo B, E receptor pathway (23), it does not interfere with proteoglycan interaction (35). The cells degraded '251-methyl-LDL-proteoglycan complex to the same extent as '25I-LDL-proteoglycan complex (data not shown). (Fig. 1) . More importantly, since the lysine and arginine residues of LDL are involved in both receptor binding and complex formation with proteoglycan (25, 40, 41) , continued association with proteoglycan effectively blocks the positive charges of LDL and thus prevents cellular uptake via the apo B, E receptor.
We also considered the possibility that the proteoglycan or hyaluronic acid in the complexes might be the ligands carrying the lipoprotein into the cells. However, this was ruled out because earlier we observed that excess proteoglycan and hyaluronic acid did not prevent the binding of '25I-LDL-proteoglycan complex in macrophages (35, 36).
Fibronectin was identified in the affinity-purified fibrous plaque complex. Earlier, Hoff and Clevidence (42) also identified this protein in large cholesteryl ester-rich particles isolated from human atherosclerotic lesions. A receptor that recognizes fibronectin has been reported on macrophages (43) and probably exists in foam cells as well. The receptor shows greater affinity when fibronectin is complexed to other connective tissue components (43) . Falcone and Salisbury (44) have reported that fibronectin stimulates the uptake of LDL-heparincollagen complexes in macrophages. Since the fibrous plaque complexes contain both heparin and chondroitin sulfate proteoglycan, their interaction with fibronectin can facilitate uptake of the complexes in foam cells, probably through binding to the fibronectin receptors. This could provide an additional pathway for the uptake not mediated by the scavenger receptor. Since the in vitro LDL-proteoglycan complex lacks both fibronectin and heparin, this also could explain the fact that stimulation ofcholesteryl ester synthesis induced by LDL-proteoglycan complex was less than that of the fibrous plaque complex in foam cells at equivalent cholesterol in the medium.
Compared with the in vitro LDL-proteoglycan complex, the stimulation ofcholesteryl ester synthesis mediated by the in vivo fibrous plaque complex was particularly greater during long-term incubation with cells. We found that during prolonged incubation (32 h) of the in vivo complex with macrophages, an already oxidized lipoprotein in the complex was further oxidized, probably by factors secreted by the cells. Even though the cells also oxidized LDL in the in vitro complex, the extent of oxidation was less compared with the lipoprotein in the in vivo complex. Consequently, uptake ofthe in vivo complex through the scavenger receptors is augmented by the increased oxidation of its component lipoprotein during longterm incubation with cells.
In summary, these studies show for the first time that foam cells isolated from atherosclerotic lesions metabolize lipoprotein-proteoglycan complexes via receptor-mediated endocytosis, and consequently continue to accumulate cholesteryl ester. Earlier we showed that such complexes isolated from human fatty streaks and fibrous plaques are taken up by human monocyte-derived macrophages, transforming the cells into foam cells ( 17) . Taken together these observations indicate that lipoprotein-proteoglycan complexes play a role not only in the transformation of macrophages into foam cells, but also in the continued maintenance of the foam cells in that state.
